Optimized production of T cells expressing chimeric antigen receptors through PI3K inhibition with idelalisib

被引：0
|
作者：
Stock, S. [1 ]
Hoffmann, J. -M. [1 ]
Gern, U. [1 ]
Wang, L. [1 ]
Hueckelhoven, A. [1 ]
Neuber, B. [1 ]
Schubert, M. -L. [1 ]
Schmitt, A. [1 ]
Mueller-Tidow, C. [1 ]
Dreger, P. [1 ]
Schmitt, M. [1 ]
Sellner, L. [1 ]
机构：
[1] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V723
引用
收藏
页码：212 / 212
页数：1
相关论文
共 50 条
  • [41] Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression
    Pohl, Alessandra De Paula
    Schmidt, Anja
    Zhang, Ai-Hong
    Maldonado, Tania
    Koenigs, Christoph
    Scott, David W.
    CELLULAR IMMUNOLOGY, 2020, 358
  • [42] The effect of the PI3K/AKT pathway inhibition on leiamyosarcoma cells.
    D'Amato, GZ
    Mohapatra, S
    Jove, R
    Windham, TC
    Burns, AC
    Sullivan, D
    Muro-Cacho, C
    Letson, GD
    Pledger, WJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 818S - 818S
  • [43] Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells
    Hasslacher, Sebastian
    Schneele, Lukas
    Stroh, Sebastien
    Langhans, Julia
    Zeiler, Katharina
    Kattner, Patricia
    Karpel-Massler, Georg
    Siegelin, Markus D.
    Schneider, Matthias
    Zhou, Shaoxia
    grunert, Michael
    Halatsch, Marc-Eric
    Nonnenmacher, Lisa
    Debatin, Klaus-Michael
    Westhoff, Mike-Andrew
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (05) : 1881 - 1896
  • [44] Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells
    Mamidi, Murali K.
    Mahmud, Hasan
    Maiti, Guru P.
    Mendez, Mariana T.
    Fernandes, Stacey M.
    Vesely, Sara K.
    Holter-Chakrabarty, Jennifer
    Brown, Jennifer R.
    Ghosh, Asish K.
    LEUKEMIA, 2022, 36 (07) : 1806 - 1817
  • [45] Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells
    Murali K. Mamidi
    Hasan Mahmud
    Guru P. Maiti
    Mariana T. Mendez
    Stacey M. Fernandes
    Sara K. Vesely
    Jennifer Holter-Chakrabarty
    Jennifer R. Brown
    Asish K. Ghosh
    Leukemia, 2022, 36 : 1806 - 1817
  • [46] An investigation of the anti-inflammatory effects and a potential biomarker of PI3K inhibition in COPD T cells
    Khan, Abid
    Southworth, Thomas
    Worsley, Sally
    Sriskantharajah, Srividya
    Amour, Augustin
    Hessel, Edith M.
    Singh, Dave
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (09) : 932 - 940
  • [47] Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
    Condomines, Maud
    Arnason, Jon
    Benjamin, Reuben
    Gunset, Gertrude
    Plotkin, Jason
    Sadelain, Michel
    PLOS ONE, 2015, 10 (06):
  • [48] T63 induces apoptosis in nasopharyngeal carcinoma cells through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway
    Liu, Qin
    Chen, Wei
    Yang, Huiling
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (08) : 4635 - 4645
  • [49] T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells
    Yang, Dong
    Su, Bin
    Dai, Hongjiu
    Li, Wenxuan
    Shi, Lan
    Zhang, Peixian
    Li, Shirong
    Zhao, Xudong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [50] Expression of PI3K Signaling Associated with T Cells in Psoriasis Is Inhibited by Seletalisib, a PI3Kδ Inhibitor, and Is Required for Functional Activity
    Yager, Nicole
    Haddadeen, Ciara
    Powell, Mark
    Payne, Andrew
    Allen, Rodger
    Healy, Eugene
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (06) : 1435 - 1439
12345